MedPath

VIMIZIM

These highlights do not include all the information needed to use VIMIZIM safely and effectively. See full prescribing information for VIMIZIM .

Approved
Approval ID

0caa2565-12b2-0ad0-1f9a-273e81c3d4cc

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 21, 2021

Manufacturers
FDA

BioMarin Pharmaceutical Inc.

DUNS: 079722386

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

elosulfase alfa

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code68135-100
Application NumberBLA125460
Product Classification
M
Marketing Category
C73585
G
Generic Name
elosulfase alfa
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 21, 2021
FDA Product Classification

INGREDIENTS (1)

ELOSULFASE ALFAActive
Quantity: 5 mg in 5 mL
Code: ODJ69JZG85
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VIMIZIM - FDA Drug Approval Details